BioSpace News Archive

Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved eye diseases, today announced the appointment of Dr. Mohamed Genead as chair of the Ocugen, Inc. Retina Scientific Advisory Board, which is comprised of prominent experts who provide strategic advice, clinical and regulatory support, and scientific and industry expertise. Shankar Musu

Tenax Therapeutics, Inc. announced that it received notice from The Nasdaq Stock Market, LLC on June 2, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Goldman Sachs 41 st Annual Global Healthcare Conference Webcast on Wednesday, June 10, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:00 p.m. EDT. A live video webcast will be available on the “Events and Presentations” section of Elanco’s investor website at https://investor.elanco.com/investors/events-

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that it will be presenting at the 2020 Virtual Summer Summit being held on June 9 th -12 th . Ken d’Entremont, CEO and Roland Boivin, CFO are scheduled to present on Wednesday, June 10 th at 10:20 a.m. Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here . One-

Rosen is a Veteran Pharmaceutical Leader and has Held Senior Positions at Some of the World’s Top Pharmaceutical Companies

Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to 67 Cu-SARTATE™, a therapy for the clinical management of neuroblastoma. The FDA defines a “rare pediatric diseas

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel wound care and biosurgical devices, will be featured as a presenting company at the Virtual Summer Summit. The conference is being held on June 9-12, 2020. Chief Executive Officer, Terrence W. Norchi, MD, is scheduled to provide a corporate update on Wednesday, June 10th at 1:35 PM ET. Dr. Norchi will be available for 1x1 virtual meetings with investors who

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Neovasc Reducer™ device

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Diana McKenzie has been appointed to its board of directors as an independent director. Ms. McKenzie is a senior technology leader and innovator with deep experience across pharma, biotechnology and technology. She most recently served as Chief Information Officer of Workday, Inc., a cloud-based financial and human capital management software company. Prior

the most common malignant tumor. The first patient in the state was treated by Dr. Bailes, who is chairman of the department of neurosurgery and co-director of the NorthShore Neurological Institute.